Tempus AI (NASDAQ:TEM) CFO Sells $475,623.78 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 7,257 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total transaction of $475,623.78. Following the completion of the sale, the chief financial officer owned 131,216 shares of the company’s stock, valued at $8,599,896.64. This trade represents a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Tempus AI Trading Down 4.9%

NASDAQ:TEM traded down $3.40 during mid-day trading on Thursday, hitting $65.69. 7,149,431 shares of the stock traded hands, compared to its average volume of 11,236,510. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The stock has a market capitalization of $11.69 billion, a price-to-earnings ratio of -55.20 and a beta of 4.86. The firm’s 50 day moving average is $84.42 and its two-hundred day moving average is $71.91.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The firm had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. The company’s quarterly revenue was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Wall Street Analyst Weigh In

TEM has been the topic of several recent analyst reports. Morgan Stanley raised their price target on shares of Tempus AI from $68.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Piper Sandler decreased their target price on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Canaccord Genuity Group dropped their price target on Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Finally, Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $80.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. EMC Capital Management purchased a new stake in Tempus AI in the third quarter valued at about $297,000. Sunbelt Securities Inc. acquired a new position in shares of Tempus AI during the third quarter valued at about $52,000. Captrust Financial Advisors raised its position in shares of Tempus AI by 24.8% in the 3rd quarter. Captrust Financial Advisors now owns 135,066 shares of the company’s stock valued at $10,901,000 after purchasing an additional 26,853 shares during the last quarter. Danske Bank A S purchased a new position in shares of Tempus AI in the 3rd quarter valued at approximately $48,000. Finally, Advisory Services Network LLC acquired a new stake in Tempus AI in the 3rd quarter worth approximately $256,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.